Our Pricing

Understanding the Wegovy Pen: Your Complete UK Guide to Semaglutide Injection

Published on: June 03, 2026

The Wegovy pen is a pre-filled, single-use semaglutide injection device designed for once-weekly subcutaneous administration to support clinically significant weight loss in adults with obesity or overweight plus weight-related comorbidities. As a UK-registered pharmacy with thousands of patients successfully using this treatment, Cured Pharmacy offers the Wegovy pen at the cheapest UK price from £69.00, with transparent pricing and expert clinical support throughout your weight loss journey. Each pen is designed for ease of use, requiring no manual dose measurement, and delivers precise semaglutide dosing to help you achieve your weight management goals under proper medical supervision.

What Is the Wegovy Pen and How Does It Work?

The Wegovy pen is a pre-filled, single-dose injection device containing semaglutide, a GLP-1 receptor agonist licensed by the MHRA for chronic weight management in the UK [1]. Each pen delivers a specific dose subcutaneously once weekly, mimicking the action of the naturally occurring hormone GLP-1 to regulate appetite, slow gastric emptying, and improve glycaemic control. The pen design eliminates the need for vial drawing or dose calculation, making self-administration straightforward and reducing the risk of dosing errors.

Clinical trials including the STEP programme demonstrated that adults using the Wegovy pen achieved an average weight loss of 15-17% of their initial body weight over 68 weeks when combined with lifestyle modification [1]. The pen's mechanism targets multiple pathways: it enhances insulin secretion in response to meals, suppresses glucagon release, and acts on brain regions regulating appetite and food intake. This multi-faceted approach makes the Wegovy pen one of the most effective pharmaceutical interventions for obesity currently available in the UK, subject to prescriber approval following clinical assessment.

Wegovy Pen Dosing Schedule and Titration

The Wegovy pen follows a carefully structured dose escalation protocol designed to minimise gastrointestinal side effects while optimising therapeutic efficacy [2]. Treatment begins with a 0.25 mg weekly dose for the first four weeks, then increases to 0.5 mg for weeks 5-8, followed by 1 mg for weeks 9-12, 1.7 mg for weeks 13-16, and finally the maintenance dose of 2.4 mg from week 17 onwards. Each dose strength comes in a separate, colour-coded pen to prevent confusion during administration.

This gradual titration is critical for tolerability—rushing dose increases significantly raises the risk of nausea, vomiting, and treatment discontinuation [2]. Our clinical team at Cured Pharmacy guides patients through each transition, monitoring for side effects and adjusting the schedule if needed. If a dose is missed, patients should administer it within five days; if more than five days have passed, skip the missed dose and resume the regular schedule. The Wegovy pen should be injected on the same day each week, though the time of day can vary according to patient preference.

Proper Injection Technique for the Wegovy Pen

Using the Wegovy pen correctly ensures accurate dosing and reduces injection site reactions. Remove the pen from refrigeration 30 minutes before injection to allow it to reach room temperature, which improves comfort. Check the pen window to confirm the medication is clear and colourless—do not use if cloudy or discoloured. Remove both caps, place the pen perpendicular to clean skin on the abdomen, thigh, or upper arm, press firmly until you hear a click, then hold for six seconds to ensure full dose delivery [3]. Rotate injection sites weekly to minimise lipodystrophy and maintain consistent absorption. Dispose of used pens immediately in a sharps container—never reuse a Wegovy pen, as each is designed for single use only.

Wegovy Pen Price UK: Cost Comparison and Savings

At Cured Pharmacy, the Wegovy pen is available at the cheapest UK price from £69.00 per pen, with new patients receiving £20 off their first order using code Weightlossnew. This transparent pricing structure means you know the exact cost before completing your online consultation, eliminating hidden fees or unexpected charges. Our pricing remains consistently competitive across all dose strengths, ensuring affordability throughout the entire titration and maintenance phases of treatment.

The cost-effectiveness of the Wegovy pen extends beyond the purchase price when you consider the comprehensive service included: free online consultation with UK-registered prescribers, discreet next-day delivery, ongoing clinical support, and access to our pharmacist-led weight management guidance. Many patients find that investing in the Wegovy pen delivers substantial health returns through reduced comorbidity risk, improved quality of life, and decreased long-term healthcare costs associated with obesity-related conditions such as type 2 diabetes, hypertension, and cardiovascular disease [4]. All treatment requires clinical assessment and prescriber approval based on individual suitability.

Wegovy Pen Side Effects and Safety Profile

The most common side effects associated with the Wegovy pen are gastrointestinal in nature, including nausea (affecting up to 44% of users), diarrhoea, constipation, vomiting, and abdominal discomfort [5]. These symptoms typically peak during dose escalation phases and diminish over time as the body adapts to semaglutide. Eating smaller, more frequent meals, avoiding high-fat foods, and staying well-hydrated can help manage these effects. Most patients find GI symptoms tolerable and do not require treatment discontinuation when the titration schedule is followed appropriately.

Rare but serious adverse effects require immediate medical attention: symptoms of pancreatitis (severe persistent abdominal pain radiating to the back), signs of gallbladder disease, severe allergic reactions, changes in vision, or symptoms of medullary thyroid carcinoma (lump in neck, persistent hoarseness, difficulty swallowing) [5]. The Wegovy pen is contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Our clinical team screens for these contraindications during consultation and provides comprehensive safety information tailored to your medical history. Regular monitoring by your prescriber ensures any emerging concerns are addressed promptly throughout treatment.

Who Should Not Use the Wegovy Pen?

The Wegovy pen is not suitable for everyone seeking weight loss treatment. Absolute contraindications include hypersensitivity to semaglutide or any pen components, personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, pregnancy, and breastfeeding [6]. Caution is advised in patients with severe gastrointestinal disease, history of pancreatitis, diabetic retinopathy, renal impairment, or those under 18 years of age. Concurrent use with other GLP-1 receptor agonists or insulin requires careful prescriber evaluation due to increased hypoglycaemia risk. During your online consultation at Cured Pharmacy, our UK-registered clinicians assess your complete medical history, current medications, and individual risk factors to determine whether the Wegovy pen is appropriate and safe for you.

How to Store and Handle Your Wegovy Pen Safely

Proper storage of the Wegovy pen is essential to maintain medication efficacy and safety. Unused pens must be refrigerated at 2-8°C until first use, stored in the original carton to protect from light [3]. Never freeze the pen—if accidentally frozen, discard it immediately as freezing denatures the semaglutide protein and renders it ineffective. Once removed from refrigeration for injection, the pen can remain at room temperature (up to 30°C) for up to 28 days, though most patients use each pen immediately and discard it.

Always check the expiration date printed on the pen label before use and inspect the medication through the viewing window—it should be clear and colourless without particles or discolouration. Keep the Wegovy pen out of reach of children and pets, and never share pens between individuals due to infection risk. After injection, dispose of the used pen in a rigid sharps container according to local council guidelines; never throw it in household waste. Our pharmacy team provides detailed storage guidance with each order and is available to answer any handling questions throughout your treatment journey.

Wegovy Pen Results: What to Expect During Treatment

Patients using the Wegovy pen typically begin noticing appetite reduction within the first few weeks of treatment, though clinically significant weight loss generally becomes apparent after 8-12 weeks at therapeutic doses [1]. In the landmark STEP 1 trial, participants achieved an average of 15% body weight reduction over 68 weeks, with nearly one-third losing 20% or more of their initial weight [1]. However, individual results vary based on adherence to the dosing schedule, concurrent lifestyle modifications including diet and physical activity, baseline metabolic factors, and genetic predisposition.

Sustainable weight loss with the Wegovy pen requires commitment to comprehensive lifestyle changes—the medication is not a standalone solution but rather a powerful tool that works synergistically with reduced calorie intake and increased physical activity [4]. Most patients experience gradual, steady weight loss rather than rapid drops, which is physiologically healthier and more likely to be maintained long-term. Plateau periods are normal and do not indicate treatment failure; continuing the medication as prescribed and working with healthcare professionals to optimise nutrition and exercise typically restores weight loss momentum. Our clinical team at Cured Pharmacy provides ongoing support to help you maximise your results and navigate challenges throughout your weight management programme.

Monitoring Progress and Adjusting Treatment

Regular monitoring is essential when using the Wegovy pen to assess both efficacy and safety. Your prescriber will typically review weight loss progress every 12-16 weeks, evaluate tolerance of the current dose, and screen for adverse effects or complications [6]. If you have not achieved at least 5% weight loss after 12 weeks at the maintenance dose, your clinician may reassess the appropriateness of continuing treatment, as this suggests inadequate response. Conversely, patients who reach their goal weight may discuss dose reduction or alternative maintenance strategies with their prescriber. Blood pressure, lipid profiles, and glycaemic markers often improve alongside weight loss, providing additional health benefits that your healthcare team will track. At Cured Pharmacy, our follow-up consultations ensure your treatment plan remains optimised and aligned with your evolving health needs.

Scientific References

1. Wilding, J. P., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., ... & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. [accessed 13 August 2026]
2. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., ... & Wadden, T. A. (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA, 325(14), 1414-1425. [accessed 13 August 2026]
3. Novo Nordisk. (2023). Wegovy (semaglutide) injection: Prescribing information. Novo Nordisk A/S. [accessed 13 August 2026]
4. Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., ... & Wharton, S. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083-2091. [accessed 13 August 2026]
5. Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., ... & Wilding, J. P. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine, 373(1), 11-22. [accessed 13 August 2026]
6. Medicines and Healthcare products Regulatory Agency. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. MHRA. [accessed 13 August 2026]
7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.